

**Becky Ann Briesacher, Ph.D.**  
Northeastern University  
School of Pharmacy,  
360 Huntington Avenue  
Mailing: R218 TF, Office: R215  
Boston, MA 02115  
617-373-8330  
[b.briesacher@northeastern.edu](mailto:b.briesacher@northeastern.edu)

Updated: January 2023

### **Education**

- Ph.D. Pharmaceutical Health Services Research, University of Maryland, Baltimore 2001  
Thesis: *Reports of Unfilled Prescriptions in the Medicare Population.*
- M.A. Humanities, Williams College, Massachusetts 1988
- B.A. Art History, University of California, Berkeley 1986

### **Academic Appointments**

- Vice-Chair of Research, Northeastern University, Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Boston, MA 9/2018-2020
- Associate Professor, Northeastern University (tenured), Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Boston, MA 9/2014-
- Adjunct Faculty, University of Massachusetts, Quantitative Health Sciences, Worcester, MA 2009-2014
- Associate Professor of Medicine, University of Massachusetts Medical School (tenure-track), Department of Medicine, Division of Geriatric Medicine, Worcester, MA 2009-2014
- Adjunct Faculty, Graduate School Biomedical Sciences, Clinical and Population Health Research, University of Massachusetts Medical School, Worcester, MA 2005-2014
- Assistant Professor of Medicine, University of Massachusetts Medical School (tenure track position), Department of Medicine, Division of Geriatric Medicine, Worcester, MA 2004-2009
- Assistant Research Professor, University of Maryland, School of Pharmacy (non-tenure track position), Department of Pharmaceutical Health Services Research, Baltimore, MD 2002-2004

### **Other Positions and Employment**

- Director of Research, Peter Lamy Center on Drug Therapy and Aging, University of Maryland, School of Pharmacy, Baltimore, MD 2001-2004
- Director, Institute for Pharmaceutical Economics, University of the Sciences in Philadelphia (PCPS), Philadelphia, PA 1995-1997
- Director and Chair, Marvin Samson Center for the History of Pharmacy, University of the Sciences in Philadelphia (PCPS), Philadelphia, PA 1994-1997
- Senior Associate, Technology Assessment and PharmacoEconomics Services, Ben Franklin Center of Excellence, University of the Sciences in Philadelphia (PCPS), Philadelphia, PA 1992-1997
- Manager/Editorial Associate, Institute for Pharmaceutical Economics, University of the Sciences in Philadelphia (PCPS), Philadelphia, PA 1991-1995

**Publications**

*Peer-reviewed* (underline indicates a student author)

1. Lewis NJ. Patwell JT. **Briesacher BA**. The role of insurance claims databases in drug therapy outcomes research. *Pharmacoeconomics*. 4(5):323-30, 1993 Nov.
2. Wertheimer AI. **Briesacher BA**. Specialization in pharmacy: the United States experience, *International Pharmacy Journal* 1994;8:116-119.
3. McGhan WF. **Briesacher BA**. Implementing pharmacoeconomic outcomes management. *Pharmacoeconomics*. 6(5):412-6, 1994 Nov.
4. **Briesacher B**. DuChane J. Drug utilization review in the managed care environment. *Medical Interface*. 8(3):72-4, 76-8, 1995 Mar.
5. **Briesacher BA**. Erwin WG. Cornwell S. Claims Database Research. *American Druggist*. 48-55, 1995 April.
6. Erwin WG. **Briesacher BA**. Franic D. Management Overview of Chronic Nonmalignant Pain in Long Term Care, *The Consultant Pharmacist* 1995;10:1034-1049.
7. **Briesacher B**. Erwin WG. Managed care organizations: the new research partners. *Medical Interface*. 8(12):68-73, 77, 1995 Dec.
8. **Briesacher B**. Corey R. Patient satisfaction with pharmaceutical services at independent and chain pharmacies. *American Journal of Health-System Pharmacy*. 54(5):531-6, 1997 Mar 1.
9. Baran RW. Keil DP. Patterson HK. Doyle J. **Briesacher BA**. Erwin WG. Diagnosis and Treatment of Osteoporosis in Long-Term Care Facilities. *The Consultant Pharmacist*. 1998;13(6): 685-699.
10. Stuart B. **Briesacher BA**. Ahern F. Kidder D. Zacker C. Erwin G. Gilden D. Fahlman C. Drug use and prescribing problems in four state Medicaid programs. *Health Care Financing Review*. 20(3):63-78, 1999.
11. **Briesacher BA**. Stuart B. Peluso R. Drug use and prescribing problems in the community dwelling elderly: a study of three state Medicaid programs. *Clinical Therapeutics*. 21(12):2156-72, 1999 Dec
12. Stuart B. Shea D. **Briesacher B**. Dynamics in drug coverage of Medicare beneficiaries: finders, losers, switchers. *Health Affairs*. 20(2):86-99, 2001 Mar-Apr.
13. Stuart B. **Briesacher B**. Medication decisions--right and wrong. *Medical Care Research & Review*. 59(2):123-45, 2002 Jun.
14. Stuart B. Singhal PK. Fahlman C. Doshi J. **Briesacher B**. Employer-sponsored health insurance and prescription drug coverage for new retirees: dramatic declines in five years. *Health Affairs. Suppl Web Exclusives*:W3-334-41, 2003 Jul-Dec.
15. Kamal-Bahl SJ. Doshi JA. Stuart BC. **Briesacher BA**. Propoxyphene use by community-dwelling and institutionalized elderly Medicare beneficiaries. *Journal of the American Geriatrics Society*. 51(8):1099-104, 2003 Aug.
16. Stuart B. Kamal-Bahl S. **Briesacher B**. Lee E. Doshi J. Zuckerman IH. Verovsky I. Beers MH. Erwin G. Friedley N. Trends in the prescription of inappropriate drugs for the elderly between 1995 and 1999. *American Journal Geriatric Pharmacotherapy*. 1(2):61-74, 2003 Dec.
17. Kamal-Bahl S. **Briesacher B**. How do incentive-based formularies influence drug selection and spending for hypertension? *Health Affairs*. 23(1):227-36, 2004 Jan-Feb.

18. Wrobel MV, Doshi J, Stuart BC, **Briesacher B**. Predictability of prescription drug expenditures for Medicare beneficiaries. *Health Care Financing Review*. 25(2):37-46, Winter 2003-2004.
19. Shea DG, Stuart BC, **Briesacher B**. Participation and crowd-out in a Medicare drug benefit: simulation estimates. *Health Care Financing Review*. 25(2):47-61, Winter 2003-2004.
20. **Briesacher B**, Limcangco R, Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. *Health Care Financing Review*. 25(2):63-76, Winter 2003-2004.
21. **Briesacher B**, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. *Archives of Internal Medicine*. 164(15):1679-84, 2004 Aug 9-23.
22. Stuart B, Doshi JA, **Briesacher BA**, Wrobel MV, Baysac F. Impact of prescription coverage on hospital and physician costs: a case study of Medicare beneficiaries with chronic obstructive pulmonary disease. *Clinical Therapeutics* 2004; 26(10):1688-99.
23. Doshi JA, Shaffer T, **Briesacher B**. National estimates of medication use in nursing homes: Findings from the 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. *Journal of the American Geriatrics Society* 2005;53(3):438-443
24. **Briesacher B**, Limcangco R, Simoni-Wastila L, Doshi J, Gurwitz J. Evaluation of nationally mandated drug use reviews to improve patient safety in nursing homes: a natural experiment. *Journal of the American Geriatrics Society* 2005;53(6):991-996.
25. Stuart B, **Briesacher B**, Shea DG, Cooper B, Baysac FS, Limcangco MR. Riding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit. *Health Affairs* 2005; 24(4):1-10, Jul-Aug.
26. Simoni-Wastila L, Zuckerman I, Singhal P, **Briesacher BA**, Hsu V. National estimates of exposure to prescription drugs with addiction potential in community-dwelling elders. *Substance Abuse* 2005;26(1):33-42.
27. **Briesacher B**, Stuart B, Doshi J, Wrobel MV. Medicare beneficiaries and the impact of gaining prescription drug coverage on inpatient and physician spending. *Health Services Research* 2005; 40(5):1279-1296
28. **Briesacher BA**, Limcangco MR, Simoni-Wastila L, Doshi JA, Levins SR, Shea DG, Stuart B. The quality of antipsychotic prescribing in nursing homes. *Archives of Internal Medicine* 2005;165(11) 1280-1285.
29. **Briesacher BA**, Orwig D, Seton M, Omar M, Kahler K. Medical care costs of Paget's disease of bone in a privately-insured population. *Bone* 2005;37(6).
30. Toure J, Brandt N, Limcangco MR, **Briesacher BA**. Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted living facilities. *American Journal of Geriatric Pharmacotherapy* 2006; 4(1) 25-35.
31. Gaskin DJ, **Briesacher B**, Limcangco MR, Brigantti L, Lillie-Blanton M. Exploring racial and ethnic disparities in prescription drug spending and use of among Medicare beneficiaries, *American Journal of Geriatric Pharmacotherapy* 2006;4(2) 1-17.
32. Kirking DM, Lee JA, Ellis J, **Briesacher B**, McKercher P. Patient-reported underuse of prescription medications: A comparison of nine surveys. *Medical Care Research and Review* 2006;63(4) 427-446.

33. **Briesacher B.** Andrade S. Kahler KH. Yood RA. Economic impact of the previous year's adherence with bisphosphonates. *Arthritis Rheumatology* 2006;54:S85-S86.
34. Shea DG. Terza JV. **Briesacher BA.** Stuart B. Moral hazard in Medicare coverage for prescription drugs. *Health Services Research* 2007; 42(3) 933-949.
35. Stuart B. Wrobel M. Doshi JA. **Briesacher BA.** Will Part D produce savings in Part A and Part B? *Inquiry* 2007: Vol. 44, No. 2, pp. 146–156.
36. Field TS. Mazor K. Debellis K. **Briesacher BA.** Gurwitz JH. Adverse drug events resulting from patient errors among older adults. *Journal of the American Geriatrics Society* 2007;55(2)271-276.
37. **Briesacher BA.** Andrade SE. Yood RA. Kahler KH. Consequences of poor compliance with bisphosphonates. *Bone* 2007 Jul 18.
38. **Briesacher BA.** Gurwitz JH. Soumerai SB. Patients at-risk for cost-related medication nonadherence: A review of the literature. *Journal of General Internal Medicine* 2007;22(6):864-71.
39. **Briesacher BA.** Andrade SE. Fouayzi H. Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. *Pharmacotherapy* 2008;28:437-43.
40. **Briesacher BA.** Field TS. Baril J. Gurwitz JH. Can pay-for-performance take nursing home care to the next level? *Journal of the American Geriatrics Society* 2008. 56(10):1937-9.
41. Madden JM. Graves AJ. Zhang F. Adams AS. **Briesacher BA.** Ross-Degnan D. Gurwitz JH. Pierre-Jacques M. Safran DG. Adler GS. Soumerai SB. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. *JAMA* 2008. 99(16):1922-1928.
42. **Briesacher BA.** Ross-Degnan D. Adams AS. Wagner AK. Gurwitz JH. Soumerai SB. A new measure of medication affordability. *Social Work in Public Health* 2009. 24(6):600-612.
43. Tjia J. **Briesacher BA.** Soumerai SB. Pierre-Jacques M. Zhang F. Ross-Degnan D. Gurwitz JH. Medicare beneficiaries and free prescription drug samples: a national survey. *Journal of General Internal Medicine* 2008. 23(6):709-14.
44. Lau DT. **Briesacher BA.** Mercaldo ND. Halpern L. Osterberg EC. Jarzebowski M. McKoy JM. Mazor K. Older patients' perceptions of medication importance and worth: an exploratory pilot study. *Drugs & Aging*. 25(12):1061-75, 2008.
45. Tjia J. **Briesacher BA.** Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus. *Journal of the American Geriatrics Society* 2008. 56(10):1879-86.
46. Harrold LR. Andrade SE. **Briesacher BA.** Raebel MA. Fouayzi H. Yood RA. Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. *Arthritis Research & Therapy* 2009. 11(2):R46.
47. Madden JM. Graves AJ. Ross-Degnan D. **Briesacher BA.** Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. *JAMA* 2009;99(16):1922-1928.
48. **Briesacher BA.** Field TS. Baril J. Gurwitz JH. Pay-for-performance in nursing homes. *Health Care Financing Review* 2009. 30(3):1-13.
49. **Briesacher BA.** Andrade SE. Fouayzi H. Chan KA. Medication adherence and use of generic drug therapies. *American Journal of Managed Care* 2009. 15(7):450-6.

50. Tjia J. Bonner A. **Briesacher BA**. McGee S. Terrill E. Miller K. Medication discrepancies upon hospital to skilled nursing facility transitions. *Journal of General Internal Medicine* 2009. 24(5):630-5.
51. **Briesacher BA**. Soumerai SB. Field TS. Fouayzi H. Gurwitz JH. Nursing home residents and enrollment in Medicare Part D. *Journal of the American Geriatrics Society* 2009. 57(10):1902-7.
52. **Briesacher BA**. Andrade SE. Harrold LR. Fouayzi H. Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. *American Journal of Medicine* 2010. 123(3):275-80.
53. Harrold LR. Andrade SE. **Briesacher BA**. Raebel MA. Fouayzi H. Yood RA. Ockene IS. The dynamics of chronic gout treatment: medication gaps and return to therapy. *American Journal of Medicine* 2010. 123(1):54-9.
54. Tjia J. **Briesacher B**. Xie D. Fu J. Goldberg RJ. Disparities in combination drug therapy use in older adults with coronary heart disease: a cross-sectional time-series in a nationally representative US sample. *Drugs & Aging* 2010. 27(2):149-58.
55. Chen Y. Field TS. Tjia J. Lau D. Gurwitz JH **Briesacher BA**. Unexplained variation across U.S. nursing homes in antipsychotic prescribing rates. *JAMA Archives of Internal Medicine* 2010. 170(1):89-95.
56. **Briesacher BA**. Soumerai SB. Field TS. Fouayzi H. Gurwitz JH. Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes. *JAMA Archives of Internal Medicine* 2010. 170(8):693-8.
57. **Briesacher BA**, Ross-Degnan D, Wagner, AK, Fouayzi H, Zhang F, Gurwitz JH, Soumerai S. Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy. *Medical Care* 2010. 48(6):503-9, 2010.
58. **Briesacher BA**. Andrade SE. Harrold LR. Fouayzi H. Yood RA Adherence and occurrence of fractures after switching to once-monthly oral bisphosphonates. *Pharmacoepidemiology and Drug Safety* 2010. 19(12):1233-40.
59. Chen Y. **Briesacher BA**. Use of instrumental variable in prescription drug research with observational data: A systematic review. *Journal of Clinical Epidemiology* 2011. 64(6):687-700.
60. **Briesacher BA**, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. *BMC Pulmonary Medicine* 2011, 11:5.
61. **Briesacher BA**, Madden JM. Soumerai SB. Caution in generalizing part d results to medicare population. *JAMA Archives of Internal Medicine* 2011. 171(4):366-7.
62. **Briesacher BA**, Zhao Y, Madden JM. Zhang F, Adams AS, Tjia J, Ross-Degnan D, Gurwitz JH, Soumerai SB. Medicare part d and changes in prescription drug use and cost burden: national estimates for the medicare population, 2000-2007. *Medical Care* 2011: 49(9): 834-41.
63. Parsons C, **Briesacher BA**, Givens J, Chen Y, Tjia J. Intensity of cholinesterase inhibitor and memantine use in nursing home residents with advanced dementia. *Journal of the American Geriatrics Society* 2011; 59(7):1253-9.
64. **Briesacher BA**. Quittner AL. Fouayzi H. Zhang J. Swensen A. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007. *Pediatric Pulmonology*. 46(8):770-6, 2011.

65. Lau DT, **Briesacher BA**, Touchette DR, Stubbings J, Ng JH. Medicare Part D and the quality of prescription medication use in older adults. *Drugs & Aging*. 28(10):797-807, 2011.
66. Chen Y, Harrold LH, Yood R, Field T, **Briesacher BA**. Identifying patients with osteoporosis or at risk for osteoporotic fracture. *American Journal of Managed Care*, 18(2):e61-7, 2012. PMID:22435886
67. Tjia J, Gurwitz JH, **Briesacher BA**. The Challenge of Changing Nursing Home Prescribing Culture. *American Journal of Geriatric Pharmacotherapy*, 10(1):37-46, 2012. PMID:22264855
68. Harrold LR, Gurwitz JH, **Briesacher BA**. Time Trends in Medication Use and Expenditures in Older Rheumatoid Arthritis Patients. *The American Journal of Medicine*, 125(9):937.e9-15, 2012 PMID: 22682794.
69. **Briesacher BA**, Tjia J, Doubeni C, Chen Y, Rao SR. Methodological Issues in Using Multiple Years of the Medicare Current Beneficiary Survey. *Medicare & Medicaid Research*, 1(2), 2012.
70. Higgins AY, Doubeni ARB, Phillips KL, Laiyemo AO, **Briesacher BA**, Tjia J, Doubeni CA. Self-reported colorectal cancer screening of Medicare beneficiaries in family medicine vs. internal medicine practices in the United States: a cross-sectional study. *BMC Gastroenterology*, 2012 Mar 21;12:23. PMID:2243610
71. Johnson ES, Bartman BA, **Briesacher BA**, Fleming NS, Gerhard T, Kornegay CJ, Nourjah P, Sauer B, Schumock GT, Sedrakyan A, Stürmer T, West SL, Schneeweiss S. The incident user design in comparative effectiveness research. *Pharmacoepidemiology Drug Safety*. 2013 Jan;22(1):1-6. PMID:2302398
72. Harrold LR, **Briesacher BA**, Peterson D, Beard A, Madden J, Zhang F, Gurwitz JH, Soumerai SB. Cost-related Medication Nonadherence in Older Patients with Rheumatoid Arthritis. *Journal of Rheumatology*. 2013 Feb;40(2):137-43. PMID:23322458
73. **Briesacher BA**, Tjia J, Peterson D, Field TS, Gurwitz JH. Antipsychotic Use and Nursing Home Residents. *JAMA*, 2013;309(5):440-442. PMID: 23385262
74. Tjia J, Velten SJ, Parsons C, Valluri S, **Briesacher BA**. Studies to reduce unnecessary medication use in frail older adults: a systematic review. *Drugs & Aging*. 30(5):285-307, 2013 May. PMID: 23475597
75. Pimentel CB, Lapane KL, **Briesacher BA**. Medicare Part D and Long-Term Care: A Systematic Review of Quantitative and Qualitative Evidence, *Drugs & Aging* 2013 Sep;30(9):701-20. PMID:23729166
76. **Briesacher BA**, Soumerai SB, Zhang F, Toh S, Andrade SE, Wagner JL, Shoaibi A, Gurwitz JH. A critical review of methods to evaluate the impact of FDA regulatory actions. *Pharmacoepidemiology Drug Safety*. 2013 Jul 12. PMID: 23847020
77. Lemay CA, Mazor KM, Field TS, Donovan J, Kanaan A, **Briesacher BA**, Foy S, Harrold LR, Gurwitz JH, Tjia J. Knowledge of and Perceived Need for Evidence-Based Education About Antipsychotic Medications Among Nursing Home Leadership and Staff. *Journal of American Medical Directors Association*. 2013 Sep 24. PMID:24074962
78. Cuffee YL, Hargraves JL, Rosal M, **Briesacher BA**, Schoenthaler A, Person S, Hullett S, Allison J. Reported Racial Discrimination, Trust in Physicians, and Medication Adherence Among Inner-City African Americans with Hypertension. *American Journal of Public Health*. 2013 Nov;103(11):e55-62. PMID:24028222.

79. Tjia J, Field T, Lemay C, Mazor K, Pandolfi M, Spenard A, Ho SY, Kanaan A, Donovan J, Gurwitz JH, **Briesacher B**. Antipsychotic use in nursing homes varies by psychiatric consultant. *Medical Care*. 52(3):267-71, 2014 Mar. PMID
80. Naci H, Soumerai SB, Ross-Degnan D, Zhao Y, Zhang F, **Briesacher BA**, Gurwitz JH, Madden JM. Persistent Medication Affordability Problems Among Disabled Medicare Beneficiaries after Part D, 2006-2011. *Medical Care* 2014; 14 August. PMID 25122530.
81. Naci H, Soumerai SB, Ross-Degnan D, Zhao Y, Zhang F, **Briesacher BA**, Gurwitz JH, Madden JM. Medication Affordability Gains After Part D Are Eroding Among Elderly with Chronic Conditions. *Health Affairs* 2014; Aug;33(8):1435-43.
82. Tjia J, **Briesacher BA**, Petersen D, Liu Q, Andrade SE, Mitchell SL. Use of Medications with Questionable Benefit in Advanced Dementia. *JAMA Internal Medicine* 2014; Sept. 8. PMID 25201279.
83. Tjia J, Field T, Mazor K, Lemay CA, Kanaan AO, Donovan JL, **Briesacher BA**, Peterson D, Pandolfi M, Spenard A, Gurwitz JH. Dissemination of Evidence-Based Antipsychotic Prescribing Guidelines to Nursing Homes: A Cluster Randomized Trial. *Journal of the American Geriatrics Society* 2015 Jul;63(7):1289-98. PMID:2617355
84. Pimentel CB, **Briesacher BA**, Gurwitz JH, Rosen AB, Pimentel MT, Lapane KL. Pain management in nursing home residents with cancer. *Journal of the American Geriatrics Society* 2015 Apr;63(4):633-41 PMID: 25900481.
85. **Briesacher BA**, Madden JM, Zhang F, Ross-Degnan D, Soumerai SB. Did Medicare Part D affect national trends in health outcomes or hospitalization? *Annals of Internal Medicine* 2015;162(12):825-833. doi:10.7326/M14-0726.
86. Pimentel CB, Donovan JL, Field TS, Gurwitz JH, Harrold LR, Kanaan AO, Lemay CA, Mazor KM, Tjia J, **Briesacher BA**. Use of atypical antipsychotics in nursing homes and pharmaceutical marketing. *Journal of the American Geriatrics Society* 2015 Feb;63(2):297-301.
87. Saczynski JS, Rosen AB, McCammon RJ, Zivin K, Andrade SE, Langa KM, Vijan S, Pirraglia PA, **Briesacher BA**. Antidepressant Use and Cognitive Decline: The Health and Retirement Study. *American Journal of Medicine*. 2015 Jul;128(7):739-4
88. Tjia J, **Briesacher BA**. Inappropriate drug use in advanced dementia—reply. *JAMA Internal Medicine*. 2015 Feb;175(2):315-6.
89. Tjia J, Reidenberg MM, Hunnicutt JN, Paice K, Donovan JL, Kanaan A, **Briesacher BA**, Lapane KL. Approaches to gradual dose reduction of chronic off-label antipsychotics used for behavioral and psychological symptoms of dementia. *Consultant Pharmacists* 2015;30(10):599-611
90. Khodyakov D, Ochoa A, Olivieri-Mui B, Bouwmeester C, Zarowitz B, Patel M, Ching D, **Briesacher BA**. Screening Tool of Older Person's Prescriptions/Screening Tools to Alert Doctors to Right Treatment Medication Criteria Modified for U.S. Nursing Home Setting. *Journal of the American Geriatrics Society*. 2017;65(3):586-591.
91. Olivieri-Mui BL, Devlin JW, Ochoa A, Schenck D, **Briesacher B**. Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care. *Aging & Mental Health*. 2018 Apr;22(4):544-549.
92. Olivieri-Mui B, McGuire J, Cahill S, Griffith J, **Briesacher B**. People Living With HIV in U.S. Nursing Homes in the Fourth Decade of the Epidemic. *Journal Association of Nurses AIDS Care*. 2019;30(1):20-34.
93. **Briesacher BA**, Olivieri-Mui B, Devlin J, Koethe B. Nursing homes underreport antipsychotic prescribing. *Aging and Mental Health*, Nov 2020.
94. Rodgers J, **Briesacher BA**, Wallace RB, Kawachi I, Baum CF, Kim D. County-level housing affordability in relation to risk factors for cardiovascular disease among middle-

- aged adults: The National Longitudinal Survey of Youths 1979. *Health Place*. 2019;59:102194.
95. Madden JM, Shetty PS, Zhang F, **Briesacher BA**, Ross-Degnan D, Soumerai SB, Galbraith AA. Risk Factors Associated With Food Insecurity in the Medicare Population *JAMA Internal Medicine*. 2020;180(1):144-147.
  96. **Briesacher BA**, Olivieri-Mui B, Chhabra B, Koethe B. Adequacy of drug coverage in nursing Homes. *Medical Care*, 2020 May; Vol. 58 (5), pp. 427-432.
  97. Duprey MS, van den Boogaard M, van der Hoeven JG, Pickkers P, **Briesacher BA**, Saczynski JS, Griffith JL, Devlin JW. Association between incident delirium and 28- and 90-day mortality in critically ill adults: a secondary analysis. *Critical Care*. 2020;24(1):161.
  98. Olivieri-Mui B, McGuire J, Griffith J, Cahill S, **Briesacher B**. Assessing the Quality of Human Immunodeficiency Virus Care in Nursing Homes *Journal of the American Geriatrics Society*. 2020;10.1111/jgs.16359
  99. Olivieri-Mui BL, Koethe B, **Briesacher B**. Economic Barriers to Antiretroviral Therapy in Nursing Homes. *Journal of the American Geriatrics Society*. 2020;68(4):777-782.
  100. Cuffee YL, Hargraves L, Rosal M, **Briesacher BA**, Allison JJ, Hullett S. An Examination of John Henryism, Trust, and Medication Adherence Among African Americans With Hypertension. *Health Education Behavior*. 2020;47(1):162-169.
  101. Duprey MS, Devlin JW, van der Hoeven JG, et al. Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults. *Critical care medicine*. 2021;49(8):1303-1311. doi:10.1097/CCM.0000000000004976
  102. Kim D, Park C, **Briesacher BA**. Socially-isolated neighborhoods and the risk of all-cause mortality among nursing home residents in the United States: A multilevel study. *Preventive medicine reports*. 2020;21:101285. doi:10.1016/j.pmedr.2020.101285
  103. **Briesacher BA**, Koethe B, Olivieri-Mui B, et al. Association of Positive Delirium Screening with Incident Dementia in Skilled Nursing Facilities. *Journal of the American Geriatrics Society*. 2020;68(12):2931-2936. doi:10.1111/jgs.16830
  104. Park C, Kim D, **Briesacher BA**. Association of Social Isolation of Long-term Care Facilities in the United States With 30-Day Mortality. *JAMA network open*. 2021;4(6):e2113361. doi:10.1001/jamanetworkopen.2021.13361
  105. Duprey MS, Devlin JW, **Briesacher BA**, Trivison TG, Griffith JL, Inouye SK. Approaches to Optimize Medication Data Analysis in Clinical Cohort Studies. *Journal of the American Geriatrics Society*. 2020;68(12):2921-2926. doi:10.1111/jgs.16844
  106. Nekui F, Galbraith AA, **Briesacher BA**, et al. Cost-related Medication Nonadherence and Its Risk Factors Among Medicare Beneficiaries. *Medical care*. 2021;59(1):13-21. doi:10.1097/MLR.0000000000001458
  107. Duprey MS, Dijkstra-Kersten SMA, Zaal IJ, et al. Opioid Use Increases the Risk of Delirium in Critically Ill Adults Independently of Pain. *American journal of respiratory and critical care medicine*. April 2021. doi:10.1164/rccm.202010-3794OC
  108. Madden JM, Bayapureddy S, **Briesacher BA**, et al. Affordability of Medical Care Among Medicare Enrollees. *JAMA Health Forum*. 2021;2(12):e214104. Published 2021 Dec 10. doi:10.1001/jamahealthforum.2021.4104
  109. Olivieri-Mui B, McGuire J, Griffith J, Cahill S, **Briesacher B**. Exploring the Association Between the Quality of HIV Care in Nursing Homes and Hospitalization. *J Healthc Qual*. 2021;43(3):174-182. doi:10.1097/JHQ.0000000000000277
  110. **Briesacher BA**, Olivieri-Mui BL, Koethe B, Saczynski JS, Fick DM, Devlin JW, Marcantonio ER. Psychoactive medication therapy and delirium screening in skilled



- nursing facilities. *J Am Geriatr Soc.* 2022 Jan 21;. doi: 10.1111/jgs.17662. [Epub ahead of print] PubMed PMID: 35061246; NIHMSID:NIHMS1774161.
111. Holmes SD, Kuzucan A, Brandt N, et al. Examining transitions of care among nursing home residents with and without antipsychotic medication use [published online ahead of print, 2022 Jul 26]. *Aging Ment Health.* 2022;1-6. doi:10.1080/13607863.2022.2103098
112. Vo QT, Koethe B, Holmes S, Simoni-Wastila L, **Briesacher BA**. Patient Outcomes After Delirium Screening and Incident Alzheimer's Disease or Related Dementias in Skilled Nursing Facilities [published online ahead of print, 2022 Aug 15]. *J Gen Intern Med.* 2022;10.1007/s11606-022-07760-6. doi:10.1007/s11606-022-07760-6
113. Duprey MS, Devlin JW, Griffith JL, et al. Association Between Perioperative Medication Use and Postoperative Delirium and Cognition in Older Adults Undergoing Elective Noncardiac Surgery. *Anesth Analg.* 2022;134(6):1154-1163. doi:10.1213/ANE.0000000000005959
114. Gero K, Noubary F, Kawachi I, et al. Associations of state-level and county-level hate crimes with individual-level cardiovascular risk factors in a prospective cohort study of middle-aged Americans: the National Longitudinal Survey of Youths 1979. *BMJ Open.* 2022;12(1):e054360. Published 2022 Jan 19. doi:10.1136/bmjopen-2021-054360
115. Bamgbade BA, McManus DD, **Briesacher BA**, et al. Medication cost-reducing behaviors in older adults with atrial fibrillation: The SAGE-AF study [published online ahead of print, 2022 Sep 8]. *J Am Pharm Assoc.* 2022;S1544-3191(22)00300-4. doi:10.1016/j.japh.2022.08.030

### ***Books & Chapters***

1. Goppold B, **Briesacher BA**. Evaluating Pharmaceutical Costs and Outcomes in Managed Care. In: *The Role of Pharmacoeconomics in Outcomes Management*. Ed. N. Johnson and D. Nash. American Hospital Publishing, Inc., 1996.
2. Wertheimer AI, Dickson M, **Briesacher BA**. Pharmaceuticals in the health care system. In: *Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs*. Ed. Davis, P. Oxford Press, 1996.

### ***Government Reports (selected):***

1. Stuart B, Shea D, **Briesacher B**. *Trends in Prescription Drug Coverage of Medicare Beneficiaries, 1993-1997*, Report to US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation under contract No. 52-6002036, May 15, 2001.
2. **Briesacher B**, Stuart B, Doshi J. *Medication Use by Medicare Beneficiaries Living in Nursing Homes and Assisted Living Facilities*. Report to US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Office of Disability, Aging, and Long-term Care Policy under contract No. HHS-100-01-0023, <http://aspe.hhs.gov/daltcp/reports/meduse.htm> June 2002.
3. Shea D, Stuart B, **Briesacher B**, Doshi J. *The Graying of Medicare's Disabled Population*. Report to US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Office of Disability, Aging, and Long-term Care Policy under contract No. HHS-100-01-0023, <http://aspe.hhs.gov/daltcp/reports/graying.htm>, March 2002.

4. Gaskin D, **Briesacher B**. How do patterns of prescription drug coverage and use differ for White, African American, and Latino Medicare beneficiaries under 65 and 65+, Chartpack, Report to The Henry J. Kaiser Family Foundation, <http://www.kff.org/content/2003/6098/> July 2003.
5. Wrobel M, Doshi JA, Stuart B, **Briesacher B**. *Predicting Drug Expenditures for Medicare Beneficiaries*. Report to the Centers for Medicare and Medicaid Services, under contract No. 500-00-032/TO# 4, July 2003.
6. Lambrew J, **Briesacher B**. *Medicare Prescription Drug Legislation: What It Means for Rural Beneficiaries*. Report to Center for American Progress, Washington DC: September 2003. <http://www.gwhealthpolicy.org/downloads/ruralreport.pdf>
7. Stuart B, b, Doshi JA, Wrobel M. *Impact of Prescription Drug Benefits on Medicare Program Expenditures*. Report to the Centers for Medicare and Medicaid Services, under contract No. 500-00-032/TO# 4, September 2003.
8. **Briesacher B**, Limcangco R, Simoni-Wastila L, Doshi J, Gurwitz, J. *Evaluation of Drug Therapy Guidelines to Reduce the Use of Potentially Inappropriate Drug Use in Nursing Homes*. Report to Centers for Medicare and Medicaid Services, Division of Nursing Homes, October 9, 2003.
9. **Briesacher B**, Limcangco R, Simoni-Wastila L, Doshi J. *Trends in Use of Antipsychotics in Long-term Care Facilities*. Report to Centers for Medicare and Medicaid Services, Division of Nursing Homes, June, 2004.
10. **Briesacher B**, Soumerai SB, Zhang F, Toh D, Gurwitz JG. Mini-Sentinel White Paper on Methods to Evaluate FDA Regulatory Actions. Report to FDA, March 2012. [http://www.mini-sentinel.org/work\\_products/Statistical\\_Methods/Mini-Sentinel\\_Methods\\_Impact-of-FDA-Regulatory-Actions-White-Paper.pdf](http://www.mini-sentinel.org/work_products/Statistical_Methods/Mini-Sentinel_Methods_Impact-of-FDA-Regulatory-Actions-White-Paper.pdf)
11. **Briesacher B**, Burnell J, Daniel g, Dusetzina S, Freed M, Good C, Hornbuckle K, McClellan M, Ross J, Richardson E, Romine M, Sheehan, S. Safety Labeling Working Group. White Paper: A Framework for Evaluating the Impact of Prescription Drug Postmarketing Safety Labeling Changes. Report to FDA, Duke-Robert J. Margolis, Center for Health Policy, June 2019.

#### ***Invited Presentations, National***

American Delirium Society, Using Big Data to Understand and Improve Delirium-related Outcomes, Boston, MA	2019/6
Duke-FDA Workshop on Safety Labelling, Duke-Robert J Margolis, Center for Health Policy, Washington DC	2018/2
UMass Clinical and Translational Science Retreat, University of Massachusetts Medical School, Seminar, various	2011-2013
Centers for Medicare and Medicaid Services, Boston, MA	2013/5
Pharmaceutical Policy Research Seminar, Harvard Medical School, various	2014-2016
Health Services Research Colloquium, Medicare Part D in Long-term Care, Penn State University	2011/4
Research into Practice and Policy Discussion Forum, Center for Health Care Policy and Research, Commonwealth Medicine	2012-2013
Off-Label Antipsychotic Use in Nursing Homes, Brown University, Providence, RI	2008

Rosalie Wolf Interdisciplinary Geriatric Health Care Research Center Seminar Series, Division of Geriatric Medicine, various 2007-2008

Academic Conference, Commonwealth Medicine, various 2006-2007

Medical Grand Rounds, St. Vincent Hospital, Worcester MA 2007/1

Centers for Medicare and Medicaid Services, Distributing Medicare Part D Data to Research Community, Baltimore, MD 2007

***National/International Meetings (selected)***

Podium presentation, *Impact of CMS' National Partnership to Improve Dementia Care on Changes in Prevalence of Mental Health and other Diagnoses among Nursing Home Residents*, APHA, Boston, MA 2022

Podium Presentation, *Antipsychotic and Psychopharmacological Medications: Care Transitions Among Nursing Home Residents*, Gerontological Society of America, Phoenix, AZ 2021

Podium presentation, *State- and county-level total and race-based hate crime in relation to individual-level cardiovascular risk factors among middle-aged adults: The National Longitudinal Survey of Youths 1979*, Society for Epidemiologic Research, Boston, MA 2020

Poster, *In-hospital Outcomes Associated with Heart Failure among Women with Breast Cancer in the US: An Analysis of the 2012-2016 National Inpatient Data*, ISPOR, Orlando, FL 2019

Poster, *The effects of exercise on quality of life and cognitive/physical functioning in nursing home residents with dementia*, ASHP Midyear Clinical Meeting, Las Vegas, NV 2016

Poster, *Nursing Homes Underreport Use of Antipsychotics*, AcademyHealth, Seattle, WA 2016

Poster, *Evidence vs. Perceptions of Substitution Medications for Antipsychotics in Nursing Homes*, AcademyHealth, Boston, MA 2016

Poster, *Did Medicare Part D Affect National Trends in Health Outcomes or Hospitalizations?*, AcademyHealth, Minneapolis, MN 2015

Session Organizer and Chair, *Medication Use in US Nursing Homes*, American Public Health Association, Boston, MA 2013

Poster, *Medicare part d and long-term care: A systematic review of quantitative and qualitative evidence*, American Public Health Association, Boston, MA 2013

Podium presentation, *Statin use and discontinuation among nursing home residents with advanced dementia*, American Public Health Association, Boston, MA 2013

Poster, *Nationwide Variation in Antipsychotic Use in Nursing Homes*. International Society for Pharmacoepidemiologists, Barcelona, Spain. 2012

Invited Chair, *Medication Adherence, Utilization, and Expenditures*. Health Care Financing Organization, Robert Wood Johnson Foundation, AcademyHealth, Orlando, FL. 2012

Podium presentation, *Medication Affordability*, International Health Economics Association, Toronto, Canada 2011

- Invited panelist, *Impact of Medicare Part D on Drug Utilization, Health Outcomes, and Medical Spending*, AcademyHealth, Seattle, WA. 2011
- Podium presentation, *Out-of-Pocket Burden of Health Care Spending and the Adequacy of Medicare Part D*. American Society for Health Economists, Ithaca, NY. 2010
- Podium presentation, *Effect of Medicare Part D on Use of Psychoactive Drugs in Nursing Homes*. Commonwealth Medicine Research Policy Forum, Boston 2009
- Podium presentation, *Restrictive Drug Reimbursement Policies in Nursing Homes: Medicare Part D Exclusion of Benzodiazepines*. Gerontological Society of America, Washington, DC. 2008
- Featured podium presentation, *State-of-the Art and Ollie Randall Symposium: Evaluation of Medicare Part D in Nursing Homes*. Gerontological Society of America, San Francisco, CA. 2007
- Poster, *Economic Impact of the Previous Year's Adherence with Bisphosphonates*. American College of Rheumatology, Boston, MA. 2006
- Poster, *Patient Cost-sharing and Persistence with Antihypertensive Drugs*. American Society of Hypertension, New York, NY. 2006
- Poster, *Adverse Drug Events Resulting from Patient Errors*. American Geriatrics Society, Chicago, IL. 2006
- Poster, *Costs of Treating Patient's Disease in a Privately Insured Population*, Association of Bone and Mineral Research, Nashville, TN. 2005
- Podium presentation, *Treatment Costs of Paget's Disease as a Measure of Morbidity*, National Association for the Relief of Paget's Disease, Oxford, UK. 2005
- Poster, *Disease Burden and Treatment Costs of Elderly Patients with Paget's Disease*, American Geriatrics Society, Orlando, FL. 2005
- Poster, *Use of Abusable Prescription Drugs by Community-Dwelling Elders*. American Public Health Association, Washington DC. 2004
- Podium presentation, *Treatment Costs and Disease Burden of Patients with Paget's Disease*, International Society of Pharmacoeconomics and Outcomes Research, Hamburg, Germany 2004
- Podium presentation *Evaluation of Nationally-mandated Drug Use Reviews to Improve Patient Safety in Nursing Homes: A Natural Experiment*, AcademyHealth, San Diego, CA. 2004
- Poster, *Health Status and Daily Functioning as Predictors of Hospitalization in Patients Treated for Congestive Heart Failure*. American Society of Hypertension, New York, NY. 2004
- Podium presentation, *Impact of Antipsychotic Use on Antiparkinson Agents among Medicare Beneficiaries*, Annual Meeting, American Psychiatric Association, New York, NY. 2004
- Podium presentation, *Trends and Future Expectations for Employer-Sponsored Prescription Coverage for New Retiree Medicare Beneficiaries*. AcademyHealth, Nashville, TN. 2003

- Poster, *Do Physicians Use Free Drug Samples to Increase Access for Need Patients?* AcademyHealth, Nashville, TN. 2003
- Podium presentation, *Economic Effects of Benefit Design and Behavioral Parameters on Participation and Crowd-out in a Medicare Prescription Drug Benefit.* International Health Economics Association, San Francisco, CA. 2003
- Podium presentation, *Changes in Functional Disability Levels and Medical Expenditures among Elderly Persons.* International Society of Pharmacoeconomics and Outcomes Research, Arlington, VA. 2003
- Invited presentation, *Reports of Unfilled Prescriptions in the Medicare Population,* University of Michigan's Pharmaceutical Policy Summit, Washington, DC. 2003
- Podium presentation, *What Effect Do Tiered Drug Plans Have on NSAID Use?* 2002  
American College of Rheumatology, New Orleans, LA.
- Podium presentation, *Prescription Drug Use among Older Adults.* American Public Health Association, Philadelphia, PA. 2002
- Poster, *Participating and Crowd-Out in a Medicare Prescription Drug Benefit: Estimates from a Simulation.* AcademyHealth, Washington DC. 2002
- Invited presentation, *Patterns in Prescription Coverage, Use, and Cost for Medicare Beneficiaries in 1999, Medicare Prescription Drugs: Options and Possibilities,* Commonwealth Fund Roundtable, Washington DC. 2002
- Invited presentation, *Examining the Substitution Effects of Prescription Coverage on the Use of Medicare Part A and B Services: Assessment of Possible Sources of Data on Potential Comparison Groups,* *Expert Meeting on Issue Associates with Evaluating the Medicare-UMWA Waiver Demonstration,* Co-sponsored by ASPE and CMS, Washington DC. 2002
- Poster, *New Evidence on the Impact of Insurance on Use of Prescription Drugs by Medicare Beneficiaries,* International Health Economics Association, York, UK. 2001
- Poster, *Effects of Prescription Coverage on Reports of Unfilled Prescriptions.* International Health Economics Association, York, UK. 2001
- Invited presentation, *It's Time. Targeting Inappropriate Medications of the Elderly,* National Council on Patient Information and Education, Washington, DC. 2001
- Featured podium presentation, *Dynamics of Prescription Drug Coverage of Medicare Beneficiaries.* Academy for Health Services Research, Los Angeles, CA, (best paper presentation). 2000
- Invited presentation, *Medication Decisions-Right and Wrong.* Conference on Pharmaceutical Costs and Pricing Practices, US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Washington DC. 2000

## Grants

## Current

NIH-National Institute on Aging R21/R33 AG046341 (PI: Briesacher) Clarifying the relationship between Delirium and Alzheimer's disease and related dementias Delirium is common in older hospitalized adults admitted to nursing homes to recover, and is associated with negative complications including potentially misdiagnosed Alzheimer's disease, psychoactive prescribing and permanent placement. This nationwide and longitudinal study will provide a novel and robust exploration of the critical role that appropriate nursing home care plays in downstream consequence of delirium. Principal Investigator, 25%	8/1/2018- 7/30/2023 \$429,875 for R21/ \$1.2 mill for R33
NIH-National Heart Lung and Blood Institute R01 HL 138247 (PI: Kim) Comparative Assessment of Modifying Social Determinants to Reduce Cardiovascular Disease Burden and Disparities. This study investigated multiple population- and individual-level social and determinants as predictors of cardiovascular disease incidence, mortality, and risk factors and to compare and contrast their population health and economic impacts. Co-Investigator, 5%	7/1/2017- 5/31/2023 \$1,197,032
NIH-Massachusetts AI & Technology Center Early Acute Illness Detection in Persons with Dementia (PI: Saczynski) Co-Investigator, 5%	6/1/2022- 5/31/2023 \$213,000
<b>Pending/Under review</b>	
NIH-National Institute of Mental Health Changes in Affordability of and Access to Mental Health Care for Medicare Beneficiaries (PI: Madden) Co-I, 5%	4/1/2022- 3/31/2026 \$3.1 mill
NIH-National Institute on Aging Consequences of Social Isolation in Long-term Care (PI: Briesacher) Principal Investigator, 25%	4/1/2023- 3/31/2027 \$1.3 mil
NIH-National Institute on Aging Impact of federal policies in disparities at the end of life care among nursing home residents with Alzheimer's disease or related dementia (PI: Zhang) Co-I, 10%	7/1/2022- 6/30/2026 \$1 mill
NIH-National Institute on Aging Multimorbidity and Palliative Care among Nursing Home Residents with Alzheimer's Disease or related Dementia (PI: Zhang) Co-I, 10%	4/1/2023- 3/31/2025 \$800,000

**Completed (last 10 years)**

NIH-National Institute on Aging R21 AG028745 (PI: Madden) Patient Cost Burden and Underuse of Care in the US Medicare Population This study conducted comprehensive analyses of new federal survey measures of medical cost burden and cost-related underuse among Medicare enrollees. Role: Co-Investigator, 25%	9/01/2018- 8/31/2020 \$450,000
NIH-National Institute on Aging R01 AG046341 (PI: Briesacher) Gaps in Medicare Part D Self-Enrollment & Nursing Home Residents This study examined the effects of Part D enrollment policies on the drug coverage, out-of-pocket drug costs, medications, and health outcomes of nursing home residents. Principal Investigator, 40%	2014-2020 \$1,328,318
NIH-National Institute on Aging R21AG049269-01 (Briesacher) Consequences of Reducing Antipsychotic Prescribing in Nursing Homes This study explored antipsychotic use and therapeutic substitution before and after the reduction campaign. Understanding the consequences of targeted prescribing initiatives will provide needed information to improve dementia care in nursing homes. Principal Investigator, 25%	2015-2020 \$424,875
NIH-National Institute on Aging R01AG028745 (Soumerai) Changes in Cardiovascular Care and Outcomes in Eight Years after Medicare Part D This study examined changes in drug and non-drug utilization (inpatient and outpatient services, medications and CRN, costs), and health outcomes (acute hospital events, perceived health status) following Part D implementation among beneficiaries with cardiovascular disease. Site Principal Investigator, 20%	2011-2015 \$1,356,128
Donaghue Foundation (Tjia) Evaluating a Resident-Centered Patient Care Intervention The goal of this project was to conduct an evaluation of a statewide intervention in Massachusetts that aims to improve the quality of care and reduce antipsychotic medication use among elderly residents of nursing facilities. Co-investigator, 10%	2014-2015 \$121,718
NIH-National Institute on Aging R21AG046839 (Lapane) In-hospital Antipsychotic Use among Elderly Patients Discharged to Nursing Homes This study explored antipsychotic use in the hospital setting among older adults discharged from hospital to nursing homes	2012-2014 \$456,042

NIH-National Institute on Aging K01AG031836 (Briesacher) Cost-related Nonadherence and the Health of Older Adults. The overall goal of this project is to improve understanding of CRN, with emphasis on how the financial instability generated by rising cost-sharing impacts the health of older adults. Principal Investigator	2008–2013 \$624,268
Agency for Healthcare Research and Quality (AHRQ) R18HS019351 (Gurwitz) iADAPT: Off-Label Use of Antipsychotics in the Nursing Home The overall aim of this proposed study is to conduct a needs assessment for the nursing home setting relevant to the AHRQ CERESG entitled “Off-Label Use of Atypical Antipsychotic Drugs.” Co-Investigator	2010-2013 \$1,487,080
Agency for Healthcare Research and Quality (AHRQ) R21 HS19579 (Tjia) Optimizing Chronic Disease Prevention and Management in Advanced Dementia The goal of this project is to describe the use and outcomes of inappropriate medications by nursing home residents with advanced dementia. Co-Investigator	2010-2012 \$499,209
NIH-National Institute on Aging K01AG031836-S (Briesacher) Cost-related Nonadherence and the Health of Older Adults. Administrative Supplement Principal Investigator	2010–2011 \$53,932
Food and Drug Administration HHSF223200910061/HHSF22301002T (Briesacher) Mini-Sentinel White Paper on Methods to Evaluate Impact of FDA Regulatory Actions	2012 \$61,968
NIH-National Institute on Aging R01AG028745 (Soumerai) Evaluation of Medicare Part D and Cost-related Underuse of Medications Co-Investigator	2006–2011 \$1,491,480

**Educational Activities**

***Teaching***

Applied Drug Information (PHMD 5560, Section 2)	Course Coordinator 20 PharmD students	Northeastern University, School of Pharmacy	Fall 2019- present
--	--	--	-----------------------



Capstone (PHMD 5600)	Preceptor 2-7 PharmD students per term	Northeastern University, School of Pharmacy	Spring 2016- present
Evidence-based Medicine (PHMD 5223)	Course Coordinator 3-5 PharmD students	Northeastern University, School of Pharmacy	Spring- present
Evidence-based Medicine (PHMD 5223)	Lecturer 120 PharmD students	Northeastern University, School of Pharmacy	Fall 2019
Evidence-based Medicine (PHMD 5223)	Course Coordinator 135-138 PharmD students, new course	Northeastern University, School of Pharmacy	Fall 2016- 2018
Bouve Geriatrics Interprofessional Seminar (HLTH 1010)	Lecturer 20 students	Northeastern University, Bouvé College	Fall 2015
Research CO-OP Research APPE (PHMD 6446)	Preceptor 1 PharmD Student Preceptor 1 PharmD student	Northeastern University, School of Pharmacy Northeastern University, School of Pharmacy	Summer 2015 Spring 2015
Use Existing Population Based Public Health Data	Lecturer 6-8 graduate students	UMass Medical School Clinical and Population Health Research PhD Program	2013-2014
Summer Research Boot Camp	Seminar Leader 15 post-doctoral students	UMass Medical School Clinical Investigation	2013-2014
Design of Observational Studies and Clinical Trials	Lecturer 6-8 graduate students	UMass Medical School Clinical Investigation	2010-2014
Geriatric Medicine Fellowship	Faculty Preceptor 1 post-doctoral student	UMass Medical School	2010-2014
Evidence Based Medicine Conference	Faculty Preceptor 2-3 residents	UMass Medical School	2009-2014
Advanced Analytic Methods in Health Outcomes Research	Course Master 5 graduate students, new course	UMass Medical School Clinical and Population Health Research PhD Program	2008-2014
Epidemiology and Biostatistics	Small Group Leader	UMass Medical School	2008-2014

	10-14 medical students	Department of Family Medicine and Community Health	
Epidemiology and Research Methods	Lecturer 6-8 graduate students	UMass Medical School Clinical and Population Health Research	2007-2009
Health Policy and the Practice of Medicine Interclerkship	Small Group Leader	UMass Medical School Office of Medical Education	2005-2014
Economics of Aging	Lecturer	University of Maryland, Baltimore, MD	2005-2014
Health Care for Aging Population	Lecturer	Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD	2003
Advanced Research Methods	Lecturer	University of Maryland, Baltimore, MD	2003
Study Design and Analysis	Lecturer	University of Maryland, School of Pharmacy Baltimore, MD	2000
Health Policy Forum	Lecturer	Thomas Jefferson University Hospital, Philadelphia, PA	1995-1997
Pharmacy Systems Management	Lecturer	Pharmacy Systems Management, Philadelphia College of Pharmacy and Science, Philadelphia, PA	1995-1996

### **Graduate Advising & Supervision**

#### *Thesis Research Advisory Committee*

Quynh Vo, Antibiotic Use in Long-term Care, Northeastern University	2020-
Matthew DuPrey, Critical Care Research Fellow, Northeastern University	2017-2021
Camilla Benedicto, Use of Opioids for Cancer Pain Management in Nursing Homes, Clinical and Population Health Research, University of Massachusetts, Chair	2013-2015
Eric Smith, Comparative Effectiveness of Lithium versus Valproate in Preventing Suicide among Veterans with Mental Disorders, Millennium PhD program, University of Massachusetts, Chair	2011-2013
Lisa Lines, Outpatient Emergency Utilization, Clinical and Population Health Research, Chair	2011-2014
Yendelela Cuffee, Psychosocial and Behavioral Determinants of Medication Nonadherence among African Americans with Hypertension, Clinical and Population Health Research, University of Massachusetts	2009-2012

Yat (Gary) Leung, Quality of Diabetic Care for People with Severe Mental Illnesses, Clinical and Population Health Research, University of Massachusetts	2007-2010
Rhona Limcangco, Prevalence and Analgesic Treatment of Pain in the Medicare Nursing Home Population, Pharmaceutical Health Services Research, University of Maryland	2004-2005
<i>Thesis Mentor</i>	
Brianne Olivieri-Mui, HIV Quality of Care in Nursing Homes, Population Health, Northeastern University, AHRQ-sponsored dissertation award (R36 HS025662), Chair	2016-2019
Camilla Benedicto, Use of Opioids for Cancer Pain Management in Nursing Homes, Clinical and Population Health Research, Chair	2011-2013
Yong Chen, Comparative Effectiveness of Alendronate and Risedronate on the Risk of Non-vertebral Fractures in Older Women: An Instrumental Variables Approach Clinical and Population Health Research	2009-2011
<i>Resident</i>	
Ailis Clyne, MD, MS, Preventive Medicine Resident, Department of Family Medicine and Community Health	2009
<i>Faculty</i>	
Chanhyun Park, PharmD, PhD, Northeastern University, Department of Pharmacy and Health Systems Sciences	2018-2021
Jeanne Madden, ScD, Northeastern University, Department of Pharmacy and Health Systems Sciences	2015-2022
Leslie Harrold, MD, MPH, University of Massachusetts Medical School, Department of Rheumatology	2008-2014
Jennifer Tjia, MD, MS, University of Massachusetts Medical School, Division of Geriatric Medicine	2006-2014
<b>Service</b>	
<i>Committee Assignments, Northeastern University</i>	
Member, Research Computing Advisory Committee, Northeastern University	2018-
Member, Scholarships and Awards Committee, School of Pharmacy	2019-2022
Member, Academic Standing Committee, School of Pharmacy	2022-
Member, INVEST Faculty Search Committee, Bouvé College of Health Sciences	2022-
Chair, Research Strategic Priorities Committee, DPHSS, School of Pharmacy	2015-2019
Chair, Faculty Search Committee, DPHSS, School of Pharmacy	2017-
Member, Chair Search Committee, DPHSS, School of Pharmacy	2017-2019
Member, Tenure & Promotion Committee, DPHSS, School of Pharmacy	2015-
Chair, Sabbatical and Merit Committee, Bouvé College of Health Sciences	2018-2019
Member, Sabbatical and Merit Committee, Bouvé College of Health Sciences	2015-2020

Member, Faculty Research Development and Mentoring, School of Pharmacy	2015-2019
Member, Dean's Search Committee, Bouvé College of Health Sciences	2015-2017
Member, Admissions Committee, Population Health PhD Program, Health Sciences	2015-2016
Member, Curriculum Committee, Population Health PhD Program, Health Sciences	2015-2016

***Committee Assignments, University of Massachusetts/State***

Chair, Recruitment Committee, Clinical and Population Health Research Search Committee, Director Clinical and Population Health Research	2013-2014
Antipsychotic Task Force, Bureau of Health Care Safety and Quality, Massachusetts Department of Public Health	2011
Gave testimony, Joint Committee on Health Care Financing, Massachusetts Legislature	2010-2012
UMMS representative, Gerontology Advisory Board, Colleges of Worcester Consortium	2009
Curriculum Committee, Clinical and Population Health Research	2008-2010
Admissions Committee, Clinical and Population Health Research	2007-2009
	2005-

***Committee Assignments, National***

Standing Member, Health Services Organization and Delivery Study Section, National Institutes of Health	2019-2023
Ad hoc reviewer, Health Services Organization and Delivery Study Section, National Institutes of Health	2017-2018
Invited Expert Panel Member, Medicare Current Beneficiary Survey Redesign Study Expert Panel Meeting, Centers for Medicare and Medicaid Services	2014
Member, Board of Advisors for National Center for Health Statistics/AcademyHealth Health Policy Fellowship.	2013-2016
Standing reviewer, Improving Methods for Conducting Patient-Centered Outcomes Research, Patient-Center Outcomes Research Institute	2013-
Standing reviewer, Health Systems Research study section, Agency for Healthcare Research and Quality	2010-2017
Workgroup member, AHRQ DECIDE Research Network, Working Paper Series on "Good Research Practice"	2008-2010
Program Director, Massachusetts College of Pharmacy and Health Sciences Fellowship	2008-2010
Reviewer, Changes in Health Care Financing and Organization (HCFO) Initiative, Robert Wood Johnson Foundation	2007-2014

***Committee Assignments, International***

Expert Panel on the Development of Core Outcome Set for Medicines Management Interventions in People with Dementia, Primary Care Pharmacy, Queen's University, Belfast, Ireland	2017
Consensus Panel on Indicators of Prescribing Quality in Long-Term Care, Institute for Clinical Evaluative Sciences, Toronto, Canada	2010

**Honors and Awards**

Gerald Schumacher Pharmacy Faculty Award, Northeastern University, School of Pharmacy	2017
National Institute for Health Care Management Foundation Annual Research Award, invited nominee	2016
AAMC Mid-Career Women Faculty Professional Development Seminar Invited Participant	2009
The Brookdale Foundation, Leadership in Aging Fellowship Finalist	2008
State-of-the Art and Ollie Randall Symposium Award, Gerontological Society of America	2007
Medical Care, Exceptional Reviewer	2006-2008
American Geriatrics Society, Comorbid Disease and Multiple Morbidity in an Aging Society Fellow	2005
National Institute on Aging, Summer Institute Fellow	2004
International Society of Pharmacoeconomics and Outcomes Research, Award of Distinction	2004
MEDSTAT, MarketScan Investigator's Award	2003
Health Care Financing Administration, Dissertation Fellowship	2001
University of Maryland, Graduate Merit Award	1997
Williams College, Graduate Fellowship	1986-1988

**Professional Memberships and Activities**

American Public Health Association	2013-2017
American Society of Health Economists	2009-2012
Gerontological Society of America	2002-2010
International Society of Pharmacoepidemiology	1998-2015
International Health Economics Association	1998-2015
International Society of Pharmaceutical Outcome Research	1996-2000
AcademyHealth	1995-

**Editorial Responsibilities**

JAMA, Reviewer	2007-
Archives of General Psychiatry, Reviewer	2007-
Drugs & Aging, Reviewer	2006-
Inquiry, Reviewer	2006-
Journal of Health Care for the Poor and Underserved, Reviewer	2005-
Health Services Research, Reviewer	2004-
Journal of American Geriatrics Society, Reviewer	2003-
JAMA-Internal Medicine, Reviewer	2002-
Medical Care, Reviewer	2001-
Journal of General Internal Medicine, Reviewer	2001-
Health Affairs, Reviewer	2001-2009
Clinical Therapeutics, Reviewer	2001-